A detailed history of Barclays PLC transactions in Vaxxinity, Inc. stock. As of the latest transaction made, Barclays PLC holds 2 shares of VAXX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 29,835 99.99%
Holding current value
$0
Previous $21,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.05 - $0.71 $1,491 - $21,181
-29,833 Reduced 99.99%
2 $0
Q1 2024

May 15, 2024

SELL
$0.62 - $0.86 $17,767 - $24,645
-28,657 Reduced 48.99%
29,835 $21,000
Q4 2023

Feb 15, 2024

BUY
$0.7 - $1.31 $35,488 - $66,414
50,698 Added 650.47%
58,492 $49,000
Q3 2023

Nov 07, 2023

SELL
$1.25 - $3.0 $1,046 - $2,511
-837 Reduced 9.7%
7,794 $10,000
Q2 2023

Aug 03, 2023

BUY
$1.73 - $2.79 $14,931 - $24,080
8,631 New
8,631 $22,000

Others Institutions Holding VAXX

About Vaxxinity, Inc.


  • Ticker VAXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 112,150,000
  • Description
  • Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...
More about VAXX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.